X4 Pharmaceuticals Dividendi e riacquisti
Criteri Dividendo verificati 0/6
X4 Pharmaceuticals non ha registrato alcun pagamento di dividendi.
Informazioni chiave
n/a
Rendimento del dividendo
-61.3%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | -61.3% |
| Rendimento futuro dei dividendi | n/a |
| Crescita dei dividendi | n/a |
| Prossima data di pagamento dei dividendi | n/a |
| Data di stacco del dividendo | n/a |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | n/a |
Aggiornamenti recenti su dividendi e riacquisti
Nessun aggiornamento
Recent updates
Aggiornamento della narrazione • Jun 17
XFOR: Chronic Neutropenia Opportunity Will Drive Future Stock Upside Potential
Analysts have raised their 12 month price target on X4 Pharmaceuticals stock from $10 to $12, citing a more constructive view of the company’s lead program mavorixafor and its potential in the large, underpenetrated chronic neutropenia market. What’s in the News for X4 Pharmaceuticals X4 Pharmaceuticals received European Commission marketing authorization for XOLREMDI (mavorixafor) capsules to treat patients aged 12 and older with WHIM syndrome in the European Union, following a positive opinion from the EMA’s Committee for Medicinal Products for Human Use.
Aggiornamento della narrazione • Jun 03
XFOR: Chronic Neutropenia Opportunity Will Drive Future Upside Potential
Narrative Update on X4 Pharmaceuticals The consensus analyst price target for X4 Pharmaceuticals has moved to $12, with analysts pointing to the potential of lead drug mavorixafor in chronic neutropenia and WHIM syndrome as the main factor in their valuation analysis. Analyst Commentary Bullish analysts are highlighting X4 Pharmaceuticals as a focused rare disease story centered on mavorixafor, with both chronic neutropenia and WHIM syndrome at the core of their views.
Aggiornamento della narrazione • May 20
XFOR: Single Asset CXCR4 Platform Is Poised To Drive Upside
Analysts have lifted their price target on X4 Pharmaceuticals to $11.67 from $8.00, citing a stronger outlook for mavorixafor as a potential first in class oral CXCR4 antagonist in WHIM syndrome and primary chronic neutropenia. They note that the current valuation does not fully reflect its role as the company's key value driver.Aggiornamento della narrazione • May 04
XFOR: Single CXCR4 Hematology Program Will Drive Future Upside Potential
Analysts have raised their price target on X4 Pharmaceuticals to $12, citing what they view as significant upside potential from mavorixafor as a key value driver for WHIM syndrome and primary chronic neutropenia, along with a current valuation that they see as not fully reflecting this opportunity. Analyst Commentary Recent Street research frames X4 Pharmaceuticals as a focused hematology company, with attention centered on mavorixafor as a potential first in class oral CXCR4 antagonist for WHIM syndrome and primary chronic neutropenia.Aggiornamento della narrazione • Apr 20
XFOR: CXCR4 Program In WHIM And Chronic Neutropenia Will Drive Future Upside
Analysts have reset their price target on X4 Pharmaceuticals to $12, citing Guggenheim's recent initiation, which highlights mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary The latest Street research frames X4 Pharmaceuticals as closely tied to the success of mavorixafor in WHIM syndrome and primary chronic neutropenia.Aggiornamento della narrazione • Apr 05
XFOR: Mavorixafor Franchise Is Expected To Drive Future Upside Potential
Narrative Update Analysts have raised their price target for X4 Pharmaceuticals to $12, citing the perceived upside in mavorixafor as a key value driver and updating fair value assumptions to $10.00, along with adjusted growth, margin, discount rate, and future P/E inputs. Analyst Commentary Recent research points to mavorixafor as the central piece of the X4 Pharmaceuticals story, with coverage initiating at a $12 price target that aligns with the view of the drug as a key value driver.Aggiornamento della narrazione • Mar 22
XFOR: WHIM And Chronic Neutropenia Program Will Drive Future Upside
Analysts have adjusted their price target on X4 Pharmaceuticals to $12, noting what they view as potential upside tied to mavorixafor as a key value driver in WHIM syndrome and primary chronic neutropenia. Analyst Commentary Recent commentary from bullish analysts centers on how mavorixafor could reshape the risk reward profile for X4 Pharmaceuticals, especially as the program advances in WHIM syndrome and primary chronic neutropenia.Aggiornamento della narrazione • Mar 07
XFOR: EU WHIM Decision And Chronic Neutropenia Program Will Drive Upside Potential
Analysts have reset their price target for X4 Pharmaceuticals to $13.00, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E that they see as better aligned with the company’s current risk and earnings profile. What's in the News The European Medicines Agency's CHMP adopted a positive opinion recommending marketing authorization, under exceptional circumstances, for mavorixafor to treat WHIM syndrome in the EU (Key Developments).Aggiornamento della narrazione • Feb 21
XFOR: Higher Fair Value Will Reflect Stronger Outlook Despite Margin Headwinds
Analysts have lifted their fair value estimate for X4 Pharmaceuticals from $4.00 to $5.00 per share, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key drivers of the new price target. Valuation Changes Fair Value was raised from $4.00 to $5.00 per share, an increase of 25% in the modelled estimate.Aggiornamento della narrazione • Feb 06
XFOR: Fair Value View Will Balance Dilution Concerns And Execution Milestones
Analysts have lifted their price target on X4 Pharmaceuticals to $4.00 per share from $4.00, citing updated assumptions around revenue growth, discount rate, profit margin, and future P/E that are now reflected in their models. Valuation Changes Fair Value: Maintained at $4.00 per share, with no change from the prior estimate.Aggiornamento della narrazione • Jan 23
XFOR: Future Outlook Weighs October Financing Dilution Against Execution And Earnings Milestones
Narrative Update Analysts have trimmed their 12 month price target on X4 Pharmaceuticals to US$7.50 from US$9.00, mainly reflecting updated financing assumptions after the recent earnings report and the October capital raise. Analyst Commentary Bearish analysts are using the latest earnings report and the October capital raise to reset expectations on X4 Pharmaceuticals, with the 12 month price target update to US$7.50 at the center of their view.Aggiornamento della narrazione • Jan 09
XFOR: Future Outlook Balances October Financing Dilution With Execution And Earnings Milestones
Analysts have trimmed their 12 month price target for X4 Pharmaceuticals to US$7.50 from US$9.00, citing updated financing assumptions following the October capital raise as well as recent earnings and corporate updates. Analyst Commentary Bearish analysts are framing the lower US$7.50 12 month price target as a reset that reflects updated expectations after recent earnings and the October capital raise.Articolo di analisi • Dec 24
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Shares May Have Run Too Fast Too Soon
With a median price-to-sales (or "P/S") ratio of close to 12.4x in the Biotechs industry in the United States, you...Aggiornamento della narrazione • Dec 22
XFOR Future Outlook Weighs Financing Dilution Against Long Term Commercial Upside
Analysts have trimmed their price target on X4 Pharmaceuticals by $1.50 to $7.50, citing updated models that factor in revised financing assumptions following the company’s recent earnings report and October capital raise. Analyst Commentary Bearish analysts have pointed to the latest target cut as evidence that X4 Pharmaceuticals faces a more challenging path to value creation than previously modeled, with revised financing assumptions weighing on upside potential.Aggiornamento della narrazione • Dec 07
XFOR: Recent Financing Will Support Key Phase 3 Progress And Upside Potential
Analysts have modestly trimmed their fair value estimate for X4 Pharmaceuticals, cutting the price target from $9.00 to $7.50, as updated models incorporate revised financing assumptions following the company's recent capital raise. Analyst Commentary Analyst updates following the latest earnings report and corporate update emphasize that the lower price target is primarily a function of revised financing assumptions rather than a fundamental shift in the long term outlook for X4 Pharmaceuticals.Aggiornamento della narrazione • Nov 23
XFOR: Leadership Overhaul And Fresh Capital Will Drive Pipeline Progress
Analysts have revised their price target for X4 Pharmaceuticals downward from $8.70 to $7.38. They cite updated financing assumptions and recent corporate developments as key factors behind the adjustment.Aggiornamento della narrazione • Sep 25
US Launch And EMA Approval Will Expand Global Reach
Amid leadership changes and a recapitalization that add near-term execution risk despite long-term potential for mavorixafor in a substantial unmet market, analysts have lowered their price target for X4 Pharmaceuticals from $19.75 to $8.70. Analyst Commentary Leadership overhaul and new senior management introduce execution uncertainty but may improve strategic direction.Aggiornamento della narrazione • Sep 02
US Launch And EMA Approval Will Expand Global Reach
Analysts have lowered their price target for X4 Pharmaceuticals from $23.25 to $19.75, citing increased execution risks and near-term uncertainty from a leadership overhaul, tempered by optimism over recent recapitalization and the long-term potential of mavorixafor. Analyst Commentary Recent complete overhaul of the senior leadership team introduces uncertainty but also the potential for strategic renewal.Aggiornamento della narrazione • Aug 19
US Launch And EMA Approval Will Expand Global Reach
A significant reduction in X4 Pharmaceuticals’ future P/E signals lower growth expectations or improved earnings outlook, while a decreased discount rate indicates lower perceived risk, contributing to a sharp downward revision in the fair value estimate from $41.08 to $23.25. What's in the News X4 Pharmaceuticals completed a private placement, issuing 11,040,776 shares at $1.42 and 48,852,772 pre-funded warrants at $1.419, raising $85 million, led by Coastlands Capital LP and supported by top life science investors.Articolo di analisi • Aug 12
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) Revenues Are Not Doing Enough For Some Investors
You may think that with a price-to-sales (or "P/S") ratio of 0.3x X4 Pharmaceuticals, Inc. ( NASDAQ:XFOR ) is...
Nuova narrazione • Mar 30
US Launch And EMA Approval Will Expand Global Reach
The transition to a commercial-stage pharmaceutical and strategic international partnerships could significantly boost revenue growth and international market presence.Seeking Alpha • Jul 02
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data
Summary X4 Pharmaceuticals, Inc. stock price dropped due to the discontinuation of Phase II study for chronic neutropenia, but the potential market for mavorixafor is substantial. X4 Pharmaceuticals is targeting rare diseases with mavorixafor, approved for WHIM syndrome, and moving forward with a Phase III trial for CN. X4 Pharmaceuticals has the potential for significant growth with mavorixafor addressing multiple rare diseases, but faces risks including FDA approval and market penetration. I discuss why I am attempting to "catch the falling knife." Read the full article on Seeking AlphaArticolo di analisi • Mar 26
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Articolo di analisi • Apr 19
Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Oct 07
Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di XFOR siano rimasti stabili in passato.
Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di XFOR siano aumentati.
Rendimento dei dividendi rispetto al mercato
| X4 Pharmaceuticals Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (XFOR) | n/a |
| Fondo del 25% del mercato (US) | 1.3% |
| Top 25% del mercato (US) | 4.1% |
| Media del settore (Biotechs) | 2.3% |
| Analista previsionale (XFOR) (fino a 3 anni) | n/a |
Dividendo notevole: Impossibile valutare il rendimento dei dividendi di XFOR rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Dividendo elevato: Impossibile valutare il rendimento dei dividendi di XFOR rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.
Distribuzione degli utili agli azionisti
Copertura degli utili: Dati insufficienti per calcolare il payout ratio di XFOR per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché XFOR non ha segnalato alcun pagamento.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/06 19:03 |
| Prezzo dell'azione a fine giornata | 2026/07/02 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
X4 Pharmaceuticals, Inc. è coperta da 9 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Leah Rush Cann | Brookline Capital Markets |
| Arlinda Lee | Canaccord Genuity |
| Michael Schmidt | Guggenheim Securities, LLC |